Send to:

Choose Destination
See comment in PubMed Commons below
J Rheumatol. 2003 Jul;30(7):1624-5.

Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease.

Author information

  • 1Service de Médecine Interne, Hôpital Henri-Mondor, Créteil, France.


Infliximab, a chimeric anti-tumor necrosis factor-alpha monoclonal antibody, has been demonstrated to be efficient and safe in patients with active rheumatoid arthritis and in the management of severe bouts of Crohn's disease. However, the safety of infliximab has not been evaluated in patients infected with hepatitis B virus. We report the case of a 28-year-old woman, with a positive hepatitis B virus surface antigen, who developed fulminant hepatitis 2 weeks after receiving a second infliximab infusion for a refractory adult onset Still's disease.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk